How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.
Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.
Farrukh Awan, MD, MS, discusses recent advances and clinical data in CLL that led to an updated online treatment decision support tool for CLL from Clinical Care Options.
Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?
In this CME-certified interactive virtual presentation, gain case-based expert insights on incorporating targeted therapies into the treatment paradigm for CLL.
Download these slides to review the most recent clinical data on targeted therapies in both frontline and relapsed/refractory CLL.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with CLL with those of 5 renowned experts.
Jeff P. Sharman, MD; Nichole Fisher, RN, BSN; and Emily Bucholtz, RPh, review patient cases and supporting clinical data to provide guidance on optimizing care for chronic lymphocytic leukemia.
Download these slides to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.
Download this PDF resource to review the current treatment algorithm and key clinical trials in CLL.